| Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant J Lopez Bernal, N Andrews, C Gower, E Gallagher, R Simmons, ... New England Journal of Medicine 385 (7), 585-594, 2021 | 3193 | 2021 |
| Covid-19 vaccine effectiveness against the Omicron (B. 1.1. 529) variant N Andrews, J Stowe, F Kirsebom, S Toffa, T Rickeard, E Gallagher, ... New England Journal of Medicine 386 (16), 1532-1546, 2022 | 2108 | 2022 |
| Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative … JL Bernal, N Andrews, C Gower, C Robertson, J Stowe, E Tessier, ... bmj 373, 2021 | 1269 | 2021 |
| COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study VJ Hall, S Foulkes, A Saei, N Andrews, B Oguti, A Charlett, E Wellington, ... The Lancet, 2021 | 798 | 2021 |
| Duration of protection against mild and severe disease by Covid-19 vaccines N Andrews, E Tessier, J Stowe, C Gower, F Kirsebom, R Simmons, ... New England Journal of Medicine 386 (4), 340-350, 2022 | 601 | 2022 |
| Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study B Taylor, E Miller, R Lingam, N Andrews, A Simmons, J Stowe Bmj 324 (7334), 393-396, 2002 | 505 | 2002 |
| Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England N Andrews, J Stowe, F Kirsebom, S Toffa, R Sachdeva, C Gower, ... Nature medicine 28 (4), 831-837, 2022 | 368 | 2022 |
| Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis E Miller, N Andrews, L Stellitano, J Stowe, AM Winstone, J Shneerson, ... Bmj 346, 2013 | 350 | 2013 |
| Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United Kingdom does not support a causal association N Andrews, E Miller, A Grant, J Stowe, V Osborne, B Taylor Pediatrics 114 (3), 584-591, 2004 | 324 | 2004 |
| Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines S Black, J Eskola, CA Siegrist, N Halsey, N MacDonald, B Law, E Miller, ... The Lancet 374 (9707), 2115-2122, 2009 | 314 | 2009 |
| Idiopathic thrombocytopenic purpura and MMR vaccine E Miller, P Waight, CP Farrington, N Andrews, J Stowe, B Taylor Archives of disease in childhood 84 (3), 227-229, 2001 | 307 | 2001 |
| Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database J Stowe, N Andrews, L Wise, E Miller American journal of epidemiology 169 (3), 382-388, 2009 | 283 | 2009 |
| The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England AJ Van Hoek, N Andrews, PA Waight, J Stowe, P Gates, R George, ... Journal of Infection 65 (1), 17-24, 2012 | 280 | 2012 |
| Effectiveness of COVID-19 vaccines against the Omicron (B. 1.1. 529) variant of concern N Andrews, J Stowe, F Kirsebom, S Toffa, T Rickeard, E Gallagher, ... MedRxiv, 2021.12. 14.21267615, 2021 | 262 | 2021 |
| Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older … JL Bernal, N Andrews, C Gower, J Stowe, C Robertson, E Tessier, ... MedRxiv, 2021.03. 01.21252652, 2021 | 235 | 2021 |
| Interactions between SARS-CoV-2 and influenza, and the impact of coinfection on disease severity: a test-negative design J Stowe, E Tessier, H Zhao, R Guy, B Muller-Pebody, M Zambon, ... International journal of epidemiology 50 (4), 1124-1133, 2021 | 213 | 2021 |
| Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK N Andrews, E Tessier, J Stowe, C Gower, F Kirsebom, R Simmons, ... medrxiv, 2021.09. 15.21263583, 2021 | 182 | 2021 |
| COVID-19 vaccine effectiveness against the omicron (BA. 2) variant in England FCM Kirsebom, N Andrews, J Stowe, S Toffa, R Sachdeva, E Gallagher, ... The Lancet Infectious Diseases 22 (7), 931-933, 2022 | 177 | 2022 |
| Prevalence of autism and parentally reported triggers in a north east London population R Lingam, A Simmons, N Andrews, E Miller, J Stowe, B Taylor Archives of Disease in Childhood 88 (8), 666-670, 2003 | 168 | 2003 |
| Effectiveness of BNT162b2 mRNA vaccine against infection and COVID-19 vaccine coverage in healthcare workers in England, multicentre prospective cohort study (the SIREN Study) VJ Hall, S Foulkes, A Saei, N Andrews, B Oguti, A Charlett, E Wellington, ... | 157 | 2021 |
Nick AndrewsUK Health Security Agency在 ukhsa.gov.uk 的电子邮件经过验证
